Anti-CD140a重组抗体|科研级 Olaratumab ( 奥拉妥单抗 )-Product Center-Tekbiotech-Yeast and Phage Display CRO, Expert in Nano-body and Antibody Drug Development

Anti-CD140a重组抗体|科研级 Olaratumab ( 奥拉妥单抗 )

Detailed related information Target background information Experimental Plan&FAQ Related products Recommended Services

询价与订购

Name*
Phone*
Email*
Product*
Content*

Anti-CD140a重组抗体|科研级 Olaratumab ( 奥拉妥单抗 )

instructions Contact

< >

CatNo：TKYR1233

Price

WeChat QR
Contact Us

instructions
MSDSWeChat QR
Contact Us

Detailed

Background

Plan&FAQ

Recommended

Detailed related information

Catalog Number

TKYR1233

Alias

科研级 Olaratumab ( 奥拉妥单抗 ), Anti-CD140a Recombinant Antibody, Research Grade Olaratumab

Molecular Name

Olaratumab

Size

1mg, 5mg

CAS Number

1024603-93-7

Isotype

IgG1 Kappa

Clonality

Monoclonal

Concentration

1mg/ml

Molecular Weight

154 kDa

Applications

IF, IP, Neut, FuncS, ELISA, FC

Source

CHO Cells

Purity

≥95% as determined by SDS-PAGE

Buffer

Supplied in PBS, PH7.5

Protein Chemical Formula

C6554H10076N1736O2048S40

Target

PDGFRA/PDGFR2/CD140a[Homo sapiens]

Sequence

Please contact our sales representative to learn more information about this reagents.

Background

Olaratumab, sold under the brand name Lartruvo, is a monoclonal antibody medication developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha. It was removed from the United States and European Union markets in 2019, due to insufficient proof of its medical advantage (see below "Medical uses").

Storage

该产品可在 2°C-8°C 下保存一个月，活性不会明显降低。在 -20°C 至 -80°C 下保存，可稳定保存十二个月。避免反复冻融,用冰袋运输。

NOTE

仅科研使用

Target background information

Experimental Plan&FAQ